Description
Students are advised to make their work clear and well presented, marks may be reduced for poor presentation. This includes filling your information on the cover page.
Avoid plagiarism (NO MATCHING RATIO)
All answered must be typed using Times New Roman (size 12, double-spaced) font. No pictures containing text will be accepted and will be considered plagiarism).
Read the case thoroughly and make a summary alongside reading Chapter 12 in your textbook before answering the questions of the assignment.
write references
Note. All references used should be listed by the end of your analysis, using the APA style.
Unformatted Attachment Preview
Purchase answer to see full attachment

Explanation & Answer

View attached explanation and answer. Let me know if you have any questions.
Running Head: STRATEGIC MANAGEMENT: ASSIGNMENT 3
Strategic Management: Assignment 3
Student Name
Professor Name
Course title
Date of submission
1
STRATEGIC MANAGEMENT: ASSIGNMENT 3
2
Q1
Moderna Company and Lonza Group Corporation are two companies that have formed a
strategic alliances. Modern Company is a Cambridge, Massachusetts-based biotechnology and
pharmaceutical company focused on mRNA treatments and vaccines. MRNA vaccines induce an
immunological response by using a molecule copy referred to as messenger RNA (mRNA).
Moderna Company currently sells only one commercial product: the Moderna COVID-19
Vaccine. However, the firm has 23 therapy and vaccine candidates in development testing, with
15 of them having entered medical testing against Nipah virus, HIV, and influenza (Mahase,
2020).
On the other hand, Lonza Group Company is a Swiss multinational chemicals and
biotechnology firm, located in Basel. It has other facilities in South Asia, North America and
Europe. Lonza was founded in the late nineteenth-century. Biopharmaceutical and biotechnology
companies rely on Lonza Company for product manufacturing and development and for custom
production of detection systems, services for biosciences firms, biopharmaceuticals, and
chemical synthesis capabilities (Lonza, 2021).
Q2
Moderna Company and Lonza Group Company have formed a non-equity strategic
collaboration. A non-equity strategic alliance is formed when two or more businesses agree to
combine their assets and capabilities. Moderna is pursuing a non-equity strategic cooperation
with Lonza to get a production license for Moderna's Vaccine (mRNA-1273) Against Novel
Coronavirus (Lonza, 2021). A concerted effort will use Lonza's comprehensive expertise...
